Literature DB >> 8728575

Correction of severe blepharoptosis.

W Deenstra1, P Melis, M Kon, P Werker.   

Abstract

An analysis is made of 81 patients with severe blepharoptosis who underwent correction with autogenous fascia. In case of severe blepharoptosis, which means a levator function of less than 5 mm, correction by levator resection gives insufficient results. Better results are obtained by frontalis suspension, whereby the upper eyelid is connected to the frontalis muscle using fascia lata strips according to Crawford. The operative technique is described in detail. Particular interest has been paid to the width of the vertical lid fissure and symmetry between both upper eyelids after operation. The overall results were rated satisfactory to excellent with an average of 9 mm of postoperative vertical lid fissure. Comparison of the results of unilateral versus bilateral blepharoptosis correction revealed better results in the group of bilateral ptosis correction. In 76% of the bilateral patients, there was an asymmetry of less than 0.5 mm between both palpebral fissures, while in the unilateral group this result was achieved in only 35% of the cases. Symmetry is difficult to achieve in the unilateral group, especially when the vertical lid fissure of the nonptotic eye is 10 mm or more. In these cases, correction of both upper eyelids should be considered. The best time to operate on patients with severe congenital blepharoptosis is around the age of 4 to 5 years, because lagophthalmus after operation is better tolerated and the leg has developed sufficiently to provide an adequate amount of fascia. The correction of severe blepharoptosis by frontalis suspension with autogenous fascia shows a high rate of success and few complications.

Entities:  

Mesh:

Year:  1996        PMID: 8728575     DOI: 10.1097/00000637-199604000-00004

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  9 in total

1.  Prolene frontalis suspension in paediatric ptosis.

Authors:  K Chow; N Deva; S G J Ng
Journal:  Eye (Lond)       Date:  2011-03-04       Impact factor: 3.775

2.  Two different techniques for frontalis suspension using Gore-Tex to treat severe congenital ptosis.

Authors:  Adel Galal Zaky; Sameh Saad Mandour; Marwa Aly Zaky; Asmaa Mohamed Ebrahem
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-21       Impact factor: 3.117

Review 3.  Functional results and complications of Mersilene mesh use for frontalis suspension ptosis surgery.

Authors:  P Mehta; P Patel; J M Olver
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

Review 4.  Suspensory Materials for Surgery of Blepharoptosis: A Systematic Review of Observational Studies.

Authors:  Elena Pacella; Daniele Mipatrini; Fernanda Pacella; Giulia Amorelli; Andrea Bottone; Gianpaolo Smaldone; Paolo Turchetti; Giuseppe La Torre
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

Review 5.  Surgical treatment of unilateral severe simple congenital ptosis.

Authors:  Ju-Hyang Lee; Yoon-Duck Kim
Journal:  Taiwan J Ophthalmol       Date:  2018 Jan-Mar

6.  Case Report: Botulinum Toxin-A for Complication of Exposure Keratopathy Following Frontalis-Orbicularis Oculi Muscle Flap Shortening.

Authors:  Chun-Chieh Lai; Chia-Chen Lin
Journal:  Front Med (Lausanne)       Date:  2022-04-13

7.  Surgical Treatment of Severe Ptosis by Modified Brow Suspension Technique.

Authors:  Ali Adawal Ali; Abdulhameed Abdul Majeed Hassan; Marwan Salah Salman
Journal:  Plast Surg (Oakv)       Date:  2019-10-24       Impact factor: 0.947

8.  Frontalis muscle flap suspension for the correction of congenital blepharoptosis in early age children.

Authors:  Dianju Hou; Gehong Li; Lin Fang; Bing Li
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

9.  Modified frontalis sling procedure with lid crease formation.

Authors:  Maryam Aletaha; Hossein Salour; Abbas Bagheri; Nasrin Raffati; Ali Masoudi
Journal:  J Ophthalmic Vis Res       Date:  2013-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.